PERPHENAZINE

Perphenazine Adverse Events Reported to the FDA Over Time

How are Perphenazine adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Perphenazine, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Perphenazine is flagged as the suspect drug causing the adverse event.

Most Common Perphenazine Adverse Events Reported to the FDA

What are the most common Perphenazine adverse events reported to the FDA?

Completed Suicide	41 (3.63%)
Ileus Paralytic	18 (1.59%)
Drug Interaction	17 (1.5%)
Depression	16 (1.42%)
Mental Status Changes	16 (1.42%)
Asthenia	13 (1.15%)
Fatigue	13 (1.15%)
Hypotension	12 (1.06%)
Drug Ineffective	11 (.97%)
Dystonia	11 (.97%)
Agitation	10 (.88%)
	Show More
Cardiac Arrest	10 (.88%)
Death	10 (.88%)
Drug Toxicity	10 (.88%)
Anxiety	9 (.8%)
Dysarthria	9 (.8%)
Dysphagia	9 (.8%)
Feeling Abnormal	9 (.8%)
Insomnia	9 (.8%)
Neuroleptic Malignant Syndrome	9 (.8%)
Pyrexia	9 (.8%)
Renal Failure Acute	9 (.8%)
Vomiting	9 (.8%)
Confusional State	8 (.71%)
Delirium	8 (.71%)
Fall	8 (.71%)
Nausea	8 (.71%)
Pain	8 (.71%)
Tremor	8 (.71%)
Urinary Retention	8 (.71%)
Urinary Tract Infection	8 (.71%)
Disorientation	7 (.62%)
Extrapyramidal Disorder	7 (.62%)
Hallucination, Visual	7 (.62%)
Injury	7 (.62%)
Intentional Overdose	7 (.62%)
Multiple Drug Overdose	7 (.62%)
Muscle Rigidity	7 (.62%)
Respiratory Failure	7 (.62%)
Decreased Appetite	6 (.53%)
Diarrhoea	6 (.53%)
Dizziness	6 (.53%)
Dyskinesia	6 (.53%)
Facial Paresis	6 (.53%)
Loss Of Consciousness	6 (.53%)
Overdose	6 (.53%)
Parkinsonism	6 (.53%)
Psychotic Disorder	6 (.53%)
Pyuria	6 (.53%)
Respiratory Distress	6 (.53%)
Somnolence	6 (.53%)
Suicide Attempt	6 (.53%)
Tardive Dyskinesia	6 (.53%)
Urinary Incontinence	6 (.53%)
Appendicitis Perforated	5 (.44%)
Cardio-respiratory Arrest	5 (.44%)
Leukocytosis	5 (.44%)
Metabolic Acidosis	5 (.44%)
Multiple Drug Overdose Intentional	5 (.44%)
Pneumonia	5 (.44%)
Pneumonia Aspiration	5 (.44%)
Pulmonary Embolism	5 (.44%)
Serotonin Syndrome	5 (.44%)
Speech Disorder	5 (.44%)
Weight Decreased	5 (.44%)
Weight Increased	5 (.44%)
Anger	4 (.35%)
Arthralgia	4 (.35%)
Blood Creatine Phosphokinase Increa...	4 (.35%)
Cardiolipin Antibody Positive	4 (.35%)
Cerebral Atrophy	4 (.35%)
Cognitive Disorder	4 (.35%)
Drug Hypersensitivity	4 (.35%)
Dry Mouth	4 (.35%)
Hallucination	4 (.35%)
Hallucination, Auditory	4 (.35%)
Hyperhidrosis	4 (.35%)
Hypokalaemia	4 (.35%)
Intentional Self-injury	4 (.35%)
Intestinal Perforation	4 (.35%)
Irritability	4 (.35%)
Restlessness	4 (.35%)
Road Traffic Accident	4 (.35%)
Sedation	4 (.35%)
Suicidal Ideation	4 (.35%)
Treatment Noncompliance	4 (.35%)
Abdominal Distension	3 (.27%)
Abdominal Pain	3 (.27%)
Abnormal Behaviour	3 (.27%)
Acute Respiratory Distress Syndrome	3 (.27%)
Akathisia	3 (.27%)
Amnesia	3 (.27%)
Anorexia	3 (.27%)
Antiphospholipid Antibodies Positiv...	3 (.27%)
Antipsychotic Drug Level Below Ther...	3 (.27%)
Atelectasis	3 (.27%)
Blood Pressure Increased	3 (.27%)
Burnout Syndrome	3 (.27%)
Catatonia	3 (.27%)
Condition Aggravated	3 (.27%)
Constipation	3 (.27%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Perphenazine, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Perphenazine is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Perphenazine

What are the most common Perphenazine adverse events reported to the FDA?

Neurological	60 (5.31%)
Suicidal And Self-injurious Behavio...	57 (5.04%)
Movement Disorders	51 (4.51%)
Therapeutic And Nontherapeutic Effe...	36 (3.19%)
Gastrointestinal Signs	33 (2.92%)
Medication Errors	33 (2.92%)
Respiratory	32 (2.83%)
Anxiety Disorders	30 (2.65%)
Urinary Tract Signs	30 (2.65%)
Gastrointestinal Motility And Defec...	27 (2.39%)
Deliria	23 (2.04%)
	Show More
Injuries	23 (2.04%)
Disturbances In Thinking	22 (1.95%)
Infections - Pathogen Unspecified	22 (1.95%)
Cardiac Arrhythmias	21 (1.86%)
Depressed Mood Disorders	20 (1.77%)
Decreased And Nonspecific Blood Pre...	19 (1.68%)
Psychiatric	18 (1.59%)
Lower Respiratory Tract Disorders	17 (1.5%)
Chemical Injury And Poisoning	16 (1.42%)
Epidermal And Dermal Conditions	16 (1.42%)
Muscle	16 (1.42%)
Cardiac And Vascular Investigations	15 (1.33%)
Appetite And General Nutritional	14 (1.24%)
Neuromuscular	14 (1.24%)
Hematology Investigations	13 (1.15%)
Lifestyle Issues	13 (1.15%)
Physical Examination Topics	13 (1.15%)
Mental Impairment	12 (1.06%)
Body Temperature Conditions	11 (.97%)
Mood Disorders	11 (.97%)
Sleep Disorders	11 (.97%)
Fatal Outcomes	10 (.88%)
Hepatic And Hepatobiliary	10 (.88%)
Manic And Bipolar Mood Disorders	10 (.88%)
Renal Disorders	10 (.88%)
Cranial Nerve Disorders	9 (.8%)
White Blood Cell	9 (.8%)
Electrolyte And Fluid Balance Condi...	8 (.71%)
Enzyme	8 (.71%)
Hepatobiliary	8 (.71%)
Immunology And Allergy	8 (.71%)
Joint	8 (.71%)
Musculoskeletal And Connective Tiss...	8 (.71%)
Pulmonary Vascular	8 (.71%)
Seizures	8 (.71%)
Vision	8 (.71%)
Changes In Physical Activity	7 (.62%)
Glucose Metabolism Disorders	7 (.62%)
Bacterial Infectious	6 (.53%)
Eye	6 (.53%)
Schizophrenia And Other Psychotic	6 (.53%)
Skin Appendage Conditions	6 (.53%)
Acid-base	5 (.44%)
Allergic Conditions	5 (.44%)
Menstrual Cycle And Uterine Bleedin...	5 (.44%)
Pleural	5 (.44%)
Psychiatric And Behavioural Symptom...	5 (.44%)
Gastrointestinal Ulceration And Per...	4 (.35%)
Inner Ear And Viiith Cranial Nerve	4 (.35%)
Lipid Analyses	4 (.35%)
Oral Soft Tissue Conditions	4 (.35%)
Salivary Gland Conditions	4 (.35%)
Structural Brain	4 (.35%)
Toxicology And Therapeutic Drug Mon...	4 (.35%)
Anemias Nonhemolytic And Marrow Dep...	3 (.27%)
Breast	3 (.27%)
Musculoskeletal And Connective Tiss...	3 (.27%)
Ocular Neuromuscular	3 (.27%)
Personality Disorders	3 (.27%)
Pregnancy, Labour, Delivery And Pos...	3 (.27%)
Vascular	3 (.27%)
Vascular Hypertensive	3 (.27%)
Abortions And Stillbirth	2 (.18%)
Cardiac And Vascular Disorders Cong...	2 (.18%)
Cardiac Disorder Signs	2 (.18%)
Legal Issues	2 (.18%)
Lipid Metabolism	2 (.18%)
Malabsorption Conditions	2 (.18%)
Maternal Complications Of Labour An...	2 (.18%)
Metabolic, Nutritional And Blood Ga...	2 (.18%)
Musculoskeletal And Soft Tissue Inv...	2 (.18%)
Ocular Sensory Symptoms	2 (.18%)
Ovarian And Fallopian Tube	2 (.18%)
Procedural And Device Related Injur...	2 (.18%)
Product Quality Issues	2 (.18%)
Renal And Urinary Tract Investigati...	2 (.18%)
Respiratory And Mediastinal Neoplas...	2 (.18%)
Skin Vascular Abnormalities	2 (.18%)
Tongue Conditions	2 (.18%)
Angiedema And Urticaria	1 (.09%)
Autoimmune	1 (.09%)
Bladder And Bladder Neck Disorders	1 (.09%)
Bone And Joint Injuries	1 (.09%)
Bone Disorders	1 (.09%)
Breast Neoplasms Malignant And Unsp...	1 (.09%)
Cardiac Valve	1 (.09%)
Central Nervous System Vascular	1 (.09%)
Coronary Artery	1 (.09%)
Embolism And Thrombosis	1 (.09%)
Exocrine Pancreas Conditions	1 (.09%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Perphenazine, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Perphenazine is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.